Shares are down 10% after the company missed third-quarter earnings per share estimates and reported a 7.9% year-over-year decline in revenues.
On CNBC's "Cramer's Stop Trading" segment, Cramer acknowledged that the company does have an attractive dividend yield. However, the stock is on the "butcher block" and is not worth the risk of owning.
Switching gears, Cramer had another recommendation, but one that involves cancer treatments instead of roller coasters.
Agios Pharmaceuticals (AGIO) continues to carry upside momentum. The stock is already up 270% of the year, but investors who are long should hang on to the stock, he said. The company has a "tremendous cancer treatment" and some encouraging Phase 1 data, he concluded.
-- Written by Bret Kenwell